Expand AKRO Menu
AKRO MENU

AKRO Latest Press Releases

-- June 3, 2025 --

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference Globe Newswire 7:00 AM

-- May 28, 2025 --

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference Globe Newswire 7:00 AM

-- May 12, 2025 --

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- May 10, 2025 --

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 Globe Newswire 10:00 AM

-- May 9, 2025 --

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine Globe Newswire 7:11 AM
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 Globe Newswire 6:15 AM

-- May 7, 2025 --

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference Globe Newswire 4:05 PM

-- May 5, 2025 --

Long-Term Shareholders Have Rights - If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office Globe Newswire 9:51 AM

-- April 30, 2025 --

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 Globe Newswire 7:00 AM

-- April 23, 2025 --

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm Globe Newswire 3:44 PM

-- April 7, 2025 --

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm Globe Newswire 5:59 PM

-- March 24, 2025 --

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf Globe Newswire 9:13 AM

-- February 28, 2025 --

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- February 20, 2025 --

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ) Globe Newswire 8:42 AM

-- January 30, 2025 --

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:05 PM

-- January 28, 2025 --

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 9:30 PM

-- January 27, 2025 --

Akero Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH-by Both Completer and ITT Analyses-at Week 96 in Phase 2b SYMMETRY Study Globe Newswire 6:30 AM

-- January 24, 2025 --

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH Globe Newswire 4:05 PM
Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm PRNewswire 11:01 AM